Podcast Summary
Insights from a Coronavirus Expert: History, Current Knowledge, and Future Developments: Leading coronavirus expert Dr. Stanley Perlman discusses the history, current knowledge, and potential future developments of these viruses, sharing valuable insights from his decades of research experience in cell biology, developmental biology, pediatrics, and infectious diseases.
Dr. Stanley Perlman, a leading expert on coronaviruses with decades of research experience, shares valuable insights on the history, current knowledge, and potential future developments of these viruses. From his background in cell biology and developmental biology to his focus on pediatrics and infectious diseases, Perlman's work has led him to study the interactions between coronaviruses and the brain in mice. His research has been crucial in understanding the consequences of coronavirus infections in babies and has contributed significantly to our understanding of these viruses. The conversation covers the lessons learned from SARS-1 and MERS, the advancements in knowledge since the start of the COVID-19 pandemic, and the ongoing work on therapeutics and vaccines. To gain a comprehensive understanding of coronaviruses and their impact on human health, it is recommended to listen to this podcast in conjunction with Peter Atia's previous conversation with David Watkins.
Expanding knowledge and relevance in research: Despite completing medical training early, the speaker sought a clinically active focus and a broader perspective on human diseases by studying coronaviruses and their impact on brain development for over 20 years
The speaker's desire to expand his knowledge and relevance in the field of research led him to pursue a clinically active focus, despite completing his medical training at a young age. He felt compartmentalized in his initial area of research and sought a break, while also wanting to find more relevance for human diseases. The speaker's unique background, having completed medical school in a truncated program, allowed him to gain a diverse educational experience and eventually focus on childhood development and the impact of viruses on brain development. The coronavirus family, including SARS-CoV-2, shares similarities with other viruses in its replication strategy and appearance under the microscope. The speaker's research on coronaviruses and their impact on the brain led him to study multiple sclerosis-like diseases for over 20 years before the emergence of SARS.
Coronaviruses: Large Viruses with Significant Genetic Material: Coronaviruses are large viruses with significant genetic material, coding for around 25 proteins, and play important roles in various ecosystems.
Coronaviruses, as a family, are known for their unique pattern under the microscope and their ability to infect various species, from humans to animals and even insects and snakes. Despite their differences, they all require a host to replicate. Coronaviruses are characterized by their large size, with genetic information about four times that of a polio virus, making them one of the biggest viruses in terms of RNA content. This vast genetic material codes for around 25 proteins, although the human genome, with its 20,000 genes, dwarfs the viral genome. Unlike human DNA, the vast majority of a coronavirus genome is for coding, with very little non-coding material. The evolutionary purpose of coronaviruses is still a subject of ongoing research, but it's believed that they play important roles in various ecosystems, particularly in the ocean and in the human gut.
Coronaviruses: Harmful and Beneficial Roles in Ecosystems: Coronaviruses, including those causing COVID-19, have complex roles in ecosystems, infecting various organisms and impacting human health. Their ability to infect animals influences their persistence and control in human populations.
Viruses, including coronaviruses, play complex roles in various ecosystems, both harming and benefiting different organisms. While some viruses cause diseases in humans and animals, others may have beneficial effects or help maintain ecological balance. The name "corona virus" comes from the electron microscope's observation of the virus's surface projections resembling the sun's or a crown's corona. Coronaviruses have been identified in animals since the 1930s and 40s, and many can infect both humans and animals. Some viruses, like measles, only infect humans, while others, like mouse hepatitis virus, only affect specific animal species. The ability of a virus to infect animals is an essential feature for its survival and ability to hide outside the human population. This characteristic can impact efforts to eliminate a virus from the human population. For instance, West Nile virus continues to exist in animals despite the best human vaccines, while measles spreads easily among humans due to its high R-naught value.
Viruses with human origins likely came from animals: Many viruses, like measles and HIV, originated in animals before adapting to infect humans. Some, like SARS coronaviruses, were not prioritized for vaccine development due to their mild impact on humans and the possibility of reinfection.
Many viruses, including measles and HIV, are believed to have originated from animals before adapting to infect humans. Measles is thought to have evolved from a virus in winter pests, while HIV is strongly believed to have come from non-human primates. The exact details of their evolution are still being studied. In the late 90s, before the emergence of SARS, there were only two known endemic human coronaviruses, 229E and OC43, which cause mild respiratory infections and were not prioritized for vaccine development due to their relatively low severity and the fact that people could be reinfected with them. The immune response to these viruses may be transient, leading to reinfections. It's important to note that these viruses have evolved from animal hosts and have found humans to be a more favorable host, suggesting a higher fitness in human populations. However, it's essential not to anthropomorphize the viruses and assume they have a conscious desire to infect humans. Instead, they adapt to the most favorable environment available to them.
Understanding Viruses and the Immune Response: From MS to SARS: Dr. Fauci's research journey spans from studying viruses' impact on the brain and immune response in MS to addressing emerging viruses like SARS, shaped by his expertise in virology, cell biology, immunology, and pediatrics.
The humoral and cellular immune systems play crucial roles in combating viruses, specifically focusing on the B cells and antibodies in the humoral system and T cells in the cellular system. Dr. Fauci's research journey began in the late 90s, initially focusing on how viruses, such as the one causing Multiple Sclerosis, enter the brain and the subsequent tissue destruction during the elimination process. However, by the mid 90s, his interest shifted towards understanding how viruses infect the brain and the immune response's role in clearing the virus while minimizing tissue damage. A significant turning point came with the emergence of SARS in late 2002. Initially believed to be a flu virus due to its origin in southern China, it was later identified as a coronavirus that likely spread from a live animal market. Dr. Fauci's research evolved as he delved deeper into understanding the origins, impact, and potential solutions for emerging viruses like SARS. Throughout his career, Dr. Fauci's background in virology, cell biology, immunology, and pediatrics has shaped his multifaceted approach to addressing various health crises.
SARS and MERS: Similar Transmission but Different Severity: Identifying and isolating infected individuals early is crucial in preventing further spread of viruses like SARS and MERS, despite their different transmissibility and mortality rates.
The SARS virus, which emerged in 2002, was a relatively transmissible virus with an R0 of 2 to 3. This means that on average, one person would infect two to three others. However, the virus did not readily spread before the infected person became seriously ill and was hospitalized, leading to more widespread transmission. The virus caused a deep lung infection and was not as contagious in the community. Despite the virus having a 10% mortality rate, it's likely that many more people were infected but did not develop severe symptoms or get tested. The SARS outbreak started from a single event involving an animal handler who became ill and spread the virus to others while hospitalized. The MERS coronavirus, which emerged a few years later, had a similar mode of transmission but a higher mortality rate of 35%. Both viruses highlight the importance of identifying and isolating infected individuals early to prevent further spread.
Differences Between SARS, MERS, and SARS-2: MERS, though a coronavirus like SARS and SARS-2, has less cross-immunity due to genome differences and emerged in the Arabian Peninsula in 2012, causing concern due to its high mortality rate and less transmissibility.
While SARS-1, SARS-2, and MERS are all coronaviruses, they belong to different categories due to slight differences in their genome organization and coding. This means that there is less cross-immunity between them. MERS was first identified in humans in 2012, and it's a mystery why it only emerged in the Arabian Peninsula, despite the presence of the virus in camels since the 1980s. MERS is less transmissible than SARS and is primarily spread from camels to humans, but there have been cases of human-to-human transmission in hospitals. MERS is particularly concerning due to its high mortality rate, which is estimated to be around 30%.
MERS is less transmissible than SARS due to lower R0 value and close contact requirement: MERS is less transmissible than SARS due to its lower R0 value and the need for close contact with symptomatic individuals or contaminated environments. However, the discovery of other coronaviruses in bats that can enter human cells using the same mechanism as SARS is a cause for concern.
MERS (Middle East Respiratory Syndrome) is a less transmissible virus compared to SARS (Severe Acute Respiratory Syndrome) due to its lower R0 value and the fact that it requires close contact with symptomatic individuals or contaminated environments for transmission. The virus primarily affects those with severe lung disease and has been mostly contained in hospitals due to nosocomial spread. The absence of a reservoir in animals and the ability to isolate infected individuals have contributed to the eradication of SARS. However, the discovery of other coronaviruses in bats that can enter human cells using the same mechanism as SARS raises potential concerns about the existence of other, more transmissible strains.
Potential for future deadly viruses with high transmissibility: A future virus similar to MERS or SARS could be even deadlier due to high transmissibility and severe damage in the lungs, triggering a strong immune response and high mortality rates.
While viruses like MERS and SARS are deadly when they infect humans, it's not necessarily the case that they won't have significant human-to-human transmission. The speaker suggests that there's a possibility that a future outbreak of a virus similar to MERS or SARS could be even more dangerous than current outbreaks due to both its deadly nature and high transmissibility. The speaker also notes that the viruses cause severe damage in the lungs and trigger a strong immune response, contributing to the high mortality rates. SARS and MERS both use different receptors to enter the lungs, which may explain why SARS was less transmissible than SARS-CoV-2. The speaker emphasizes that understanding the biology of these viruses is crucial in developing effective interventions to limit their spread and mitigate their impact on public health.
Mortality rate of COVID-19 may be lower than initially feared: The COVID-19 mortality rate is estimated to be around 1-2%, but high transmission leads to a larger number of deaths. Research is ongoing to understand long-term effects and potential neurological impacts.
The mortality rate of SARS-CoV-2, the virus causing COVID-19, is likely lower than initially feared and more comparable to SARS and MERS, but the large number of infections due to the virus's high transmissibility can make the overall numbers seem alarming. The mortality rate is estimated to be around 1% to 2%, but the high transmission rate leads to a larger number of deaths. Additionally, there is growing interest in understanding the long-term effects of the virus on survivors, including potential neurological impacts, although concrete evidence is currently limited. It is plausible that the immune response to the virus, rather than direct virus infection, could contribute to neurological effects. Further research is needed to fully understand the long-term consequences of COVID-19.
Early signs of COVID-19 not fully understood: Despite past experiences with SARS and MERS, the scale of COVID-19 was unexpected due to its ease of transmission and rapid spread.
Despite warnings about the potential threat of coronaviruses and past experiences with SARS and MERS, the scale of the COVID-19 pandemic was not foreseen. The early signs of the outbreak in Wuhan, China were recognized in late 2019, but the extent of human-to-human transmission was not fully understood. It wasn't until late January 2020 that the World Health Organization declared a public health emergency, and even then, the full impact of the virus was yet to be realized. The ease of travel and the virus's transmissibility contributed to its rapid spread, making it a much bigger problem than previous outbreaks. The past experiences with H5N1 and H1N1 served as reminders that a highly lethal virus may not necessarily cause a pandemic, but the unique circumstances of COVID-19 proved otherwise.
Investing in essential resources for potential pandemics: Investing in PPE, contact tracing technology, national stash of testing reagents, and immune modulating drugs can save valuable time and resources during a pandemic, regardless of the specific disease.
Preparing for a pandemic for a disease that doesn't exist yet is a challenging task. However, there are some no-regret moves that can be made, such as investing in essential resources like PPE, electronic infrastructure for contact tracing, and a national stash of reagents for testing. These investments don't require knowing the specific disease and can save valuable time and resources in the long run. Additionally, having a stockpile of immune modulating drugs could be beneficial as many infectious diseases have an overactive immune response. The discussion also highlighted the importance of being prepared and investing in resources as a hedge against potential pandemics, much like how countries keep a supply of oil as a national defense imperative.
Understanding virus behavior and strengthening immune responses: We can reduce the spread and damage of viruses like the common cold and SARS-CoV-2 by understanding their behavior and strengthening our immune responses. Herd immunity plays a role in preventing outbreaks, but the exact threshold for SARS-CoV-2 is still unknown.
While we can't completely eliminate the spread of viruses like the common cold or SARS-CoV-2, we can mitigate a significant amount of damage by understanding their behavior and strengthening our immune responses. These viruses tend to thrive in cooler, drier seasons, but the reasons for this are not fully understood. Additionally, our immunity to these viruses wanes over time, which can impact our ability to build herd immunity and effectively combat their spread. Herd immunity refers to the ratio of immune individuals in a population that can prevent the virus from spreading to susceptible individuals. For highly contagious viruses like measles, a herd immunity threshold of 95% is necessary to prevent outbreaks. For less contagious viruses like SARS-CoV-2, a lower herd immunity threshold may be sufficient. However, the exact threshold for SARS-CoV-2 is still unknown, making it crucial to continue researching the virus and our immune responses to it.
Understanding Herd Immunity and R0 Value: Herd immunity threshold varies for different viruses, with measles requiring around 95% and SARS-CoV-2 possibly only 60-70%. R0 value doesn't dictate herd immunity threshold simply, other factors like population immunity and genetic drift play a role.
The concept of herd immunity and the R0 value, which measures the contagiousness of a virus, are closely related. The higher the R0 value, the greater the need for herd immunity to prevent the spread of the virus. However, the relationship between the two is not a simple inverse one. For instance, measles, with a high R0 value, requires a herd immunity threshold of around 95%, while a virus like SARS-CoV-2, with a lower R0 value, might only require a herd immunity threshold of 60-70%. This is due to the fact that a larger percentage of the population may already have some form of immunity, either through vaccination or previous infection. Another key point is that, unlike influenza, there is currently no evidence that SARS-CoV-2 undergoes significant genetic drift, meaning it is unlikely to change into a completely different virus that would render existing immunity useless. Additionally, mild infections may not provide strong immunity, and the adaptive humoral immune response, which involves the production of IgM and IgG antibodies, may not last long after recovery. Six months after a person has a common coronavirus, there is still evidence of IgG antibodies, but the exact duration and strength of immunity is still being studied.
Pre-existing immunity to other coronaviruses and its impact on COVID-19: Studies suggest that T cell responses to COVID-19 may be influenced by previous exposure to other coronaviruses, but the clinical significance and functionality of this response are unclear due to limited data on targets and cytokine production.
The immune response to COVID-19 may involve T cells that have been sensitized by other coronaviruses, but the clinical significance and functionality of this response are not yet clear. The 2020 cell paper that looked at 20 patients who recovered from COVID-19 showed that about two-thirds of them had CD8 T cell and CD4 responses, which correlated with previous exposure to other coronaviruses. However, the T cell responses were mostly measured by activation rather than functionality, and the targets for these responses were not the usual targets seen after a wild-type SARS-CoV-2 infection. The lack of clear targets and the low levels of cytokine production make it unclear how this response contributes to protection or pathogenicity. Further studies, such as those looking at killing function and cytokine response, are needed to fully understand the role of pre-existing immunity in COVID-19.
Previous infections or vaccines may not offer significant protection against COVID-19: The immune response to past infections or vaccines can vary greatly, and there's no strong evidence that BCG or MMR vaccines offer significant protection against COVID-19. Focusing on targeted therapeutic strategies and being prepared with multiple lines of defense is a more effective approach.
Previous infections or vaccinations with viruses unrelated to SARS-CoV-2 may not offer significant protection against the coronavirus causing COVID-19. The immune response to these past infections or vaccines may vary greatly among individuals, depending on how much time has passed since their initial infection or vaccination. The BCG vaccine, which is used for tuberculosis, and the MMR vaccine have received attention for their potential cross-reactivity with SARS-CoV-2, but there's no strong evidence to support this claim. BCG has not shown enough specificity to be an effective immunotherapy against cancer, and it's unlikely to have a meaningful impact on a virus like SARS-CoV-2. Instead, focusing on targeted therapeutic strategies and being prepared with multiple lines of defense when the next pandemic arrives could be more effective approaches.
Early vs Late COVID-19 Treatment: Finding the Right Approach: Machine learning and data analysis can help identify distinct COVID-19 populations for personalized early treatment, saving lives and improving patient outcomes.
Early detection and treatment of COVID-19 or other viral diseases involves a combination of antiviral therapy and immune amplifiers, while late treatment focuses on immune modulation and respiratory support. The ideal situation is to identify patients early on and provide them with the right therapy based on their specific disease course. However, this requires accurate biomarkers to distinguish between those who will progress and those who won't. Cytokines and metabolic products are potential candidates for such biomarkers, but the challenge lies in identifying distinct populations rather than just looking at ranges. Machine learning and data analysis could help in this regard, as they can consider various factors such as age, preexisting conditions, and the temporal nature of the signature. By taking a more sophisticated approach to disease treatment and identification, we can potentially save lives and improve patient outcomes.
Understanding the durability of COVID-19 immunity: Identifying those at risk of severe disease and providing effective treatments is crucial for preventing progression. Determining markers for identification and conducting studies to monitor immune response over time is challenging.
Understanding the durability of immune response to COVID-19 is crucial for both individual protection and societal prevention of further waves. The virus has likely infected millions, possibly even hundreds of millions, of people worldwide, and the length of immunity they gain is an important question. While it's likely that those with mild disease will see waning immunity, the implications for vaccine development and herd immunity are significant. The ideal situation would be to identify those at risk of severe disease and provide them with effective treatments, such as remdesivir or immune activators, to prevent progression. However, the challenges lie in determining which markers to use for identification and how to conduct studies to monitor immune response over time. Another intriguing topic touched upon was the recent paper suggesting the virus may have originated from a lab rather than a wet market, but further investigation is needed to confirm this theory. Ultimately, the focus remains on understanding the virus's behavior and finding ways to mitigate its impact on individuals and society.
Living with SARS-CoV-2: Understanding and Preparing for the Future: SARS-CoV-2 is likely to be a long-term presence, necessitating ongoing efforts to coexist and prevent future pandemics. Developing antivirals, vaccines, and safety measures are crucial, with long-term efficacy and acceptance important considerations.
The SARS-CoV-2 virus, which causes COVID-19, is likely here to stay. It's important for society to understand how to coexist with it, as future pandemics could be even more dangerous. The discussion also touched upon the risks of vaccines and the importance of understanding secondary shedding and other factors. Herd immunity may not be achievable due to the virus's mutability. The upper respiratory transmission of SARS-CoV-2 could be a significant problem, making it a challenge to prevent in the future. While we muddle through this pandemic, it's crucial to focus on developing antivirals, vaccines, and safety measures. The long-term efficacy and acceptance of vaccines are also important considerations. The conversation emphasized the need for ongoing discussions and research to address these complex issues.
Exclusive Benefits for Members of Peter Attia Drive Podcast: Joining the Peter Attia Drive podcast grants access to exclusive content, discounts, and deeper understanding of topics through comprehensive show notes and monthly AMA episodes.
Becoming a member of the Peter Attia Drive podcast offers access to exclusive benefits, including comprehensive podcast show notes, monthly AMA episodes, a private podcast feed, short podcast clips called Qualys, and discounts on recommended products. These benefits allow listeners to deepen their understanding of the topics discussed and conveniently catch up on previous episodes. The podcast itself is for informational purposes only and does not constitute medical advice. For a full list of disclosures and potential conflicts of interest, visit peteratiamd.com/about.
